Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
Racial factors play a significant role in SSc. We evaluated differences in SSc presentations between white patients (WP), Asian patients (AP) and black patients (BP) and analysed the effects of geographical locations. Methods: SSc characteristics of patients from the EUSTAR cohort were cross-sectionally compared across racial groups using survival and multiple logistic regression analyses. Results: The study included 9162 WP, 341 AP and 181 BP. AP developed the first non-RP feature faster than WP but slower than BP. AP were less frequently anti-centromere (ACA; odds ratio (OR) = 0.4, P < 0.001) and more frequently anti-topoisomerase-I autoantibodies (ATA) positive (OR = 1.2, P = 0.068), while BP were less likely to be ACA and ATA positive than were WP [OR(ACA) = 0.3, P < 0.001; OR(ATA) = 0.5, P = 0.020]. AP had less often (OR = 0.7, P = 0.06) and BP more often (OR = 2.7, P < 0.001) diffuse skin involvement than had WP. AP and BP were more likely to have pulmonary hypertension [OR(AP) = 2.6, P < 0.001; OR(BP) = 2.7, P = 0.03 vs WP] and a reduced forced vital capacity [OR(AP) = 2.5, P < 0.001; OR(BP) = 2.4, P < 0.004] than were WP. AP more often had an impaired diffusing capacity of the lung than had BP and WP [OR(AP vs BP) = 1.9, P = 0.038; OR(AP vs WP) = 2.4, P < 0.001]. After RP onset, AP and BP had a higher hazard to die than had WP [hazard ratio (HR) (AP) = 1.6, P = 0.011; HR(BP) = 2.1, P < 0.001]. Conclusion: Compared with WP, and mostly independent of geographical location, AP have a faster and earlier disease onset with high prevalences of ATA, pulmonary hypertension and forced vital capacity impairment and higher mortality. BP had the fastest disease onset, a high prevalence of diffuse skin involvement and nominally the highest mortality.
Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study
Jaeger V. K.;Tikly M.;Xu D.;Siegert E.;Hachulla E.;Airo P.;Valentini G.;Cerinic M. M.;Distler O.;Cozzi F.;Carreira P.;Allanore Y.;Muller-Ladner U.;Ananieva L. P.;Balbir-Gurman A.;Distler J. H. W.;Czirjak L.;Li M.;Henes J.;Jimenez S. A.;Smith V.;Damjanov N.;Denton C. P.;DelGaldo F.;Saketkoo L. A.;Randone S. B.;Bannert B.;Iannone F.;Maurer B.;Jordan S.;Dobrota R.;Becker M.;Mihai C.;Becvarare R.;Tomcik M.;Bielecka O. K.;Gindzienska-Sieskiewicz E.;Karaszewska K.;Cutolo M.;Pizzorni C.;Paolino S.;Sulli A.;Ruaro B.;Alessandri E.;Riccardi A.;Giacco V.;Messitini V.;Irace R.;Kedor C.;Casteleyn V.;Hilger J.;Hoeppner J.;Rednic S.;Szabo I.;Petcu A.;Avouac J.;Camelia F.;Desbas C.;Vlachoyiannopoulos P.;Montecucco C. M.;Caporali R.;Cavagna L.;Stork J.;Inanc M.;Joven B. E.;Novak S.;Anic F.;Varju C.;Minier T.;Chizzolini C.;Allai D.;Kucharz E. J.;Kotulska A.;Kopec-Medrek M.;Widuchowska M.;Dolnicar A. S.;Coleiro B.;Gabrielli A.;Manfredi L.;Benfaremo D.;Ferrarini A.;Bancel D. F.;Hij A.;Lazzaroni M. G.;Hesselstrand R.;Wuttge D.;Andreasson K.;Martinovic D.;Bozic I.;Radic M.;Braun-Moscovici Y.;Monaco A. L.;Furini F.;Hunzelmann N.;Moinzadeh P.;Pellerito R.;Caimmi C.;Bertoldo E.;Morovic-Vergles J.;Culo I. M.;Pecher A. -C.;Santamaria V. O.;Heitmann S.;Codagnone M.;Pflugfelder J.;Krasowska D.;Michalska-Jakubus M.;Seidel M.;Hasler P.;Kretschmar S.;Kohm M.;Bajocchi G.;Salvador M. J.;Da Silva J. P.;Stamenkovic B.;Stankovic A.;Selmi C. F.;De Santis M.;Ceribelli A.;Garzanova L.;Koneva O.;Starovoytova M.;Herrick A.;Puppo F.;Negrini S.;Murdaca G.;Engelhart M.;Szucs G.;Szamosi S.;De La Puente C.;Grande C. S.;Villanueva M. J. G.;Midtvedt O.;Hoffmann-Vold A. -M.;Launay D.;Sobanski V.;Riccieri V.;Vasile M.;Stefantoni K.;Ionescu R. M.;Opris D.;Sha A.;Woods A.;Gheorghiu A. M.;Bojinca M.;Sunderkotter C.;Ehrchen J.;Ingegnoli F.;Mouthon L.;Dunogue B.;Chaigne B.;Legendre P.;Cantatore F. P.;Corrado A.;Ullman S.;Iversen L.;Von Muhlen C. A.;Pozzi M. R.;Eyerich K.;Lauffer F.;Wiland P.;Szmyrka-Kaczmarek M.;Sokolik R.;Morgiel E.;Madej M.;Vanthuyne M.;Frederic H.;Alegre-Sancho J. J.;Aringer M.;Herrmann K.;Gunther C.;Westhovens R.;De Langhe E.;Lenaerts J.;Anic B.;Baresic M.;Mayer M.;Uprus M.;Otsa K.;Yavuz S.;Granel B.;Radominski S. C.;De Souza Muller C.;FeijoAzevedo V.;Mendoza F.;Busquets J.;Popa S.;Agachi S.;Zenone T.;Pileckyte M.;Stebbings S.;Jordan S.;Mathieu A.;Vacca A.;Sampaio-Barros P. D.;Stamp L.;Solanki K.;Silva C.;Schollum J.;Barns-Graham H.;Veale D.;O'Rourke M.;Loyo E.;Tineo C.;Paulino G.;Mohamed W. A. A. A.;Rosato E.;Gigante A.;Oksel F.;Yargucu F.;Tanaseanu C. -M.;Popescu M.;Dumitrascu A.;Tiglea I.;Foti R.;Visalli E.;Benenati A.;Amato G.;Ancuta C.;Villiger P.;Adler S.;Frohlich J.;Kayser C.;Eduardo A. L.;Fathi N.;Alii S.;Ahmed M.;Hasaneen S.;El Hakeem E.;De La Pena Lefebvre P. G.;Martin J. J. G.;Sibilia J.;Chatelus E.;Gottenberg J. E.;Chifflot H.;Litinsky I.;Del Galdo F.;Abignano G.;Eng S.;Seskute G.;Butrimiene I.;Rugiene R.;Karpec D.;Pascal M.;Kerzberg E.;Bianchi W.;Bianchi B. V.;Bianchi D. V.;Barcellos Y.;Castellvi I.;Millan M.;Limonta M.;Rimar D.;Rosner I.;Slobodin G.;Couto M.;Spertini F.;Ribi C.;Buss G.;Marcoccia A.;Bondanini F.;Ciani A.;Kahl S.;Hsu V. M.;Martin T.;Poindron V.;Meghit K.;Moiseev S.;Novikov P.;Chung L.;Kolstad K.;Stark M.;Schmeiser T.;Thiele A.;Majewski D.;Zdrojewski Z.;Zaneta S.;Wierzba K.;Martinez-Barrio J.;Lopez-Longo F. J.;Bernardino V.;Moraes-Fontes M. F.;Rodrigues A. C.;Riemekasten G.;Sommerlatte S.;Jendreck S.;Arnold S.;Levy Y.;Rezus E.;Cardoneanu A.;Burlui A. M.;Pamuk O. N.;Puttini P. S.;Talotta R.;Bongiovanni S.;Poormoghim H.;Andalib E.;Almasi S.;Kotter I.;Krusche M.;Cuomo G.;Danzo F.;Masini F.;Gaches F.;Michaud M.;Cartos F.;Belloli L.;Casu C.;Sfikakis P.;Tektonidou M.;Furst D.;Feldman G. R.;Ramazan A. -M.;Nurmambet E.;Miroto A.;Suta C.;Andronache I.;Huizinga T. W. J.;De Vries-Bouwstra J.;Walker U. A.
2020-01-01
Abstract
Racial factors play a significant role in SSc. We evaluated differences in SSc presentations between white patients (WP), Asian patients (AP) and black patients (BP) and analysed the effects of geographical locations. Methods: SSc characteristics of patients from the EUSTAR cohort were cross-sectionally compared across racial groups using survival and multiple logistic regression analyses. Results: The study included 9162 WP, 341 AP and 181 BP. AP developed the first non-RP feature faster than WP but slower than BP. AP were less frequently anti-centromere (ACA; odds ratio (OR) = 0.4, P < 0.001) and more frequently anti-topoisomerase-I autoantibodies (ATA) positive (OR = 1.2, P = 0.068), while BP were less likely to be ACA and ATA positive than were WP [OR(ACA) = 0.3, P < 0.001; OR(ATA) = 0.5, P = 0.020]. AP had less often (OR = 0.7, P = 0.06) and BP more often (OR = 2.7, P < 0.001) diffuse skin involvement than had WP. AP and BP were more likely to have pulmonary hypertension [OR(AP) = 2.6, P < 0.001; OR(BP) = 2.7, P = 0.03 vs WP] and a reduced forced vital capacity [OR(AP) = 2.5, P < 0.001; OR(BP) = 2.4, P < 0.004] than were WP. AP more often had an impaired diffusing capacity of the lung than had BP and WP [OR(AP vs BP) = 1.9, P = 0.038; OR(AP vs WP) = 2.4, P < 0.001]. After RP onset, AP and BP had a higher hazard to die than had WP [hazard ratio (HR) (AP) = 1.6, P = 0.011; HR(BP) = 2.1, P < 0.001]. Conclusion: Compared with WP, and mostly independent of geographical location, AP have a faster and earlier disease onset with high prevalences of ATA, pulmonary hypertension and forced vital capacity impairment and higher mortality. BP had the fastest disease onset, a high prevalence of diffuse skin involvement and nominally the highest mortality.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11369/433245
Citazioni
8
33
29
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
